Back

Clinical determinants of oral anticoagulant selection in atrial fibrillation: insights from an Argentine registry

28 August 2026 (16:15 - 16:45)
Organised by: Logo
Congress Presentation Part of: Balancing stroke prevention and bleeding risk in atrial fibrillation Oral Anticoagulation ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Marcelo Sergio Trivi

Instituto Cardiovascular De Buenos Aires, Buenos Aires (Argentina)

4 More presentations in this session

Presentation thumbnail
Left atrial appendage occlusion versus oral anticoagulation in frail patients with atrial fibrillation: a real-world study
Professor T. Liu (Tianjin, CN)
Presentation thumbnail
Association of antithrombotic therapy with cerebral microbleeds: a cross-sectional, multicentre analysis
Mr J. Gruthoelter (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Clinical outcomes by prior OAC use and switching to edoxaban in atrial fibrillation: 2-year follow-up data from the ETNA-AF China study
Professor C. Ma (Beijing, CN)
Presentation thumbnail
Predictors of major bleeding events among Chinese patients receiving edoxaban for atrial fibrillation at 2-year follow-up
Professor C. Ma (Beijing, CN)

Access the full session

Session thumbnail
Balancing stroke prevention and bleeding risk in atrial fibrillation

The Event

Event poster

ESC Congress 2026

28 August 2026 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Patterns of anticoagulant prescribing and renal function changes in patients with atrial fibrillation
27 August 2022
thumbnail
Congress Presentation
Direct oral anticoagulants, all-cause mortality and cardiovascular events in patients with atrial fibrillation with and without obesity: a sub-analysis of the nationwide START registry.
1 September 2025
thumbnail
Webinar
How to manage elderly patients with atrial fibrillation and multiple comorbidities
12 November 2021
thumbnail
Congress Presentation
Comparing Rivaroxaban and Apixaban in GARFIELD-AF according to ROCKET AF and ARISTOTLE trial selection criteria
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources